SCHEMBL26732890

SCHEMBL26732890

O=c1[nH]nc(OC(F)(F)F)c2cc(Br)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 3/20 0.43
▸ WDR77 Q9BQA1 3/20 0.43
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ DYRK1A Q13627 4/20 0.37
▸ ROCK1 Q13464 2/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ CHEK1 O14757 3/20 0.36
▸ FLT3 P36888 3/20 0.36
▸ JAK2 O60674 3/20 0.36
▸ PIM1 P11309 2/20 0.36
▸ PRKD3 O94806 2/20 0.36
▸ MAP4K4 O95819 2/20 0.36
▸ CSF1R P07333 2/20 0.36
▸ CLK2 P49760 2/20 0.36
▸ MAP4K2 Q12851 2/20 0.36
▸ NTRK3 Q16288 2/20 0.36
▸ AURKB Q96GD4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29426556 0.94 PRMT5 (0.46) PRMT5WDR77HTTSMN1; SMN2ALDH1A1
SCHEMBL26732891 0.94 PRMT5 (0.46) PRMT5WDR77HTTSMN1; SMN2ALDH1A1
SCHEMBL20944947 0.81 PRMT5 (0.40) PRMT5WDR77ALDH1A1L3MBTL1DYRK1A
SCHEMBL26732994 0.79 PRMT5 (0.40) PRMT5WDR77HTTALDH1A1L3MBTL1
SCHEMBL26630524 0.77 PRMT5 (0.43) PRMT5WDR77SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL29426552 0.77 PRMT5 (0.43) PRMT5WDR77SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL31513494 0.76 PRMT5 (0.38) PRMT5WDR77ALDH1A1L3MBTL1DYRK1A
SCHEMBL20945200 0.75 PRMT5 (0.43) PRMT5WDR77ALDH1A1L3MBTL1DYRK1A
SCHEMBL26049203 0.75 PRMT5 (0.38) PRMT5WDR77ALDH1A1L3MBTL1DYRK1A
SCHEMBL26049201 0.75 PRMT5 (0.38) PRMT5WDR77ALDH1A1L3MBTL1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 — — US disclosed
EP-4196125-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2023-06-21 — — EP disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 — — CN disclosed
WO-2022036204-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 PRMT5 1868/4885WDR77 1384/4885HTT 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback